The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.

Katrin Marie Sjoquist,Dirkje Willemien Sommeijer,Janine M. Lombard,Linda Mileshkin,Philip Beale,Peter Grant,Penny Blomfield,Michael Quinn,Alison Maree Hadley,Peter Sykes,Yoland Antill,Rachel O’Connell,Julie Martyn,Kim Gillies,David Cannan,Val Gebski,Martin R. Stockler,Richard Edmondson,Frédéric Amant,Michael Friedlander,Anzgog, Gcig, Nhmrc Ctc

The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.

2014

TPS5621 Background: Gynaecological cancers of several pathological subtypes express estrogen and/or progesterone hormone receptors (ER/PR). Previous studies, [all or mostly] retrospective, have rep...

Keywords:

Hormone Responsive
Anastrozole
Oncology
Pathology
Medicine
Internal medicine
Estrogen
Hormone receptor
Pathological

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations